Table 3.
Patient global assessment and investigator global assessment of success (ratings of ‘excellent’ or ‘good’) during the first 24 h (evaluable patients)
| Age group (years) | Placebo-controlled trials | Active comparator trials | ||||||
|---|---|---|---|---|---|---|---|---|
| Fentanyl ITS [n/N (%)] | Placebo [n/N (%)] | OR (95% CI) [fentanyl ITS vs. placebo] | p value | Fentanyl ITS [n/N (%)] | Morphine IV PCA [n/N (%)] | OR (95% CI) [fentanyl ITS vs. morphine IV PCA] | p value | |
| Patient global assessment | ||||||||
| <65 | 258/346 (74.6) | 113/209 (54.1) | 2.55 (1.061–6.154) | 0.0365 | 731/890 (82.1) | 771/922 (83.6) | 0.896 (0.701–1.146) | 0.3832 |
| 65–74 | 60/73 (82.2) | 22/43 (51.2) | 3.561 (0.834–15.199) | 0.0863 | 207/247 (83.8) | 191/231 (82.7) | 1.105 (0.660–1.849) | 0.7050 |
| 75–84 | 23/32 (71.9) | 8/19 (42.1) | 2.255 (0.802–6.343) | 0.1232 | 103/122 (84.4) | 108/132 (81.8) | 1.228 (0.627–2.406) | 0.5497 |
| ≥85 | 3/3 (100.0) | 1/2 (50.0) | 10/12 (83.3) | 12/13 (92.3) | ||||
| Investigator global assessment | ||||||||
| <65 | 261/346 (75.4) | 112/209 (53.6) | 2.600 (1.415–4.777) | 0.0021 | 763/890 (85.7) | 798/922 (86.6) | 0.932 (0.712–1.220) | 0.6073 |
| 65–74 | 58/73 (79.5) | 23/43 (53.5) | 4.559 (0.999–20.796) | 0.0501 | 220/247 (89.1) | 198/231 (85.7) | 1.364 (0.784–2.373) | 0.2714 |
| 75–84 | 25/32 (78.1) | 9/19 (47.4) | 2.561 (0.884–7.420) | 0.0831 | 112/122 (91.8) | 115/132 (87.1) | 1.329 (0.604–2.923) | 0.4798 |
| ≥85 | 3/3 (100.0) | 1/2 (50.0) | 10/12 (83.3) | 12/13 (92.3) | ||||
OR (95% CI) and p value were based on random effect models for meta-analysis
CI confidence interval, ITS iontophoretic transdermal system, IV PCA intravenous patient-controlled analgesia, OR odds ratio